Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder

International Urogynecology Journal

Volumn 17, Issue 5, 2006, Pages 502-511

  Anderson, Rodney U ^a   MacDiarmid, Scott ^b   Kell, Sherron ^c   Barada, James H ^d   Serels, Scott ^e   Goldberg, Roger P ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ALZA CORPORATION   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e Bladder Control Center of Norwalk   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anticholinergic; Overactive bladder; Oxybutynin; Tolterodine; Treatment history; Women

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DELAYED DRUG RELEASE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERACTIVE BLADDER; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; XEROSTOMIA;

EID: 33746473539     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-005-0057-7     Document Type: Article

References (29)

1. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society. Am J Obstet Gynecol 187(1):116-126
2. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327-333
3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-776
4. Hu TW, Wagner TH, Bentkover JD et al (2003) Estimated economic costs of overactive bladder in the United States. Urology 61:1123-112
5. Brown JS, McGhan WF, Chokroverty S (2000) Comorbidities associated with overactive bladder. Am J Manag Care 6:S574-S579
6. Brown JS, Vittinghoff E, Wyman JF et al (2000) Urinary incontinence: does it increase risk for falls and fractures? J Am Geriatr Soc 48:721-725
7. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD (1999) Urinary incontinence and depression. J Urol 162:82-84
8. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR et al (2001) Health-related quality of life among adults with symptoms of overactive bladder: Results from a U.S. community-based survey. Urology 57:1044-1050
9. Stewart AL, Hays RD, Ware JE Jr (1988) The MOS Short-Form general health survey. Reliability and validity in a patient population. Med Care 26:724-735
10. Herzog AR, Fultz NH (1990) Prevalence and incidence of urinary incontinence in community-dwelling populations. J Am Geriatr Soc 38:273-281
11. Shaw C, Tansey R, Jackson C, Hyde C, Allan R (2001) Barriers to help seeking in people with urinary symptoms. Fam Pract 18:48-52
12. Dugan E, Cohen SJ, Bland DR, Preisser JS, Davis CC, Suggs PK et al (2000) The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc 48:413-416
13. Milsom I, Stewart W, Thüroff J (2000) The prevalence of overactive bladder. Am J Manag Care 6:S565-S573
14. Goepel M, Hoffmann JA, Piro M, Rübben H, Michel MC (2002) Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur Urol 41:234-239
15. Rovner ES, Wein AJ (2002) The treatment of overactive bladder in the geriatric patient. Clin Geriatr 10:20-35
16. Mostwin JL (2002) Pathophysiology: The varieties of bladder overactivity. Urology 60(5 Suppl 1):22-26 (discussion 27)
17. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M et al (1998) Behavioral vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial. JAMA 280:1995-2000
18. Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE et al (2002) Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA 288:2293-2299
19. Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6(Suppl 11):S580-S590
20. Wallace SA, Roe B, Williams K, Palmer M (2004) Bladder training for urinary incontinence in adults (Cochrane Review). In: The Cochrane library. Wiley, Chichester, UK (Issue 1)
21. Berghmans LC, Hendriks HJ, De Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE (2000) Conservative treatment of urge urinary incontinence in women: A systematic review of randomized clinical trials. BJU Int 85:254-263
22. Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 326:841-844
23. Mattiasson A, Blaakaer J, Hoye K, Wein AJ, Tolterodine Scandinavian Study Group (2003) Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91:54-60
24. Gupta SK, Sathyan G (1999) Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39:289-296
25. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS (1999) Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 161:1809-1812
26. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, Tolterodine Study Group (2001) Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57:414-421
27. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW et al (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 78:687-695
28. Ditropan XL (2004) Prescribing information. ALZA Corporation, Mountain View, CA, June 2004. Available at http://www.fda.gov/cder/foi/label/2004/20897se8-013_Ditropan_lbl.pdf
29. Detrol LA (2003) Prescribing information. Pharmacia & Upjohn, Kalamazoo, MI, July 2003